The new therapy is administered to participating patients combined with the standard, first-line treatment involving surgical extirpation of the tumour followed by radiotherapy and chemotherapy treatment with temozolomide.
The Hospital is currently the only centre in Spain undertaking a study of this nature, and for which it has recently received authorisation from the Medication Agency of the Spanish Health Ministry. It is planned to involve a sample of 37 patients for the research.
The trials have been devised and developed by the Neuro-oncology and Cell Therapy Areas of the University of Navarra Hospital, in collaboration with the Centre for Applied Medical Research (CIMA) through the Scientific and Technological Institute (ICT) of the same university. The investigation has received funding from FIS (Health Research Fund) announcement by the Ministry of Health for financing the development of non-commercial pharmaceutical drugs.
In essence, the production of the personalised vaccines is carried out at the University of Navarra Hospital’s Cell Therapy Good Manufacturing Practices Laboratory, where tumour proteins are processed and then combined with immune system cells obtained from the patient’s blood, which are taught how to organise an immune response to the tumour. These prepared items are frozen and then administered to the patient as vaccines over the following months, in combination with conventional therapy.
It should be recalled that an immunotherapy treatment with similar characteristics was developed over two years ago by a research team at CIMA and the University of Navarra Hospital. In that case, the procedure was based on the production and administration of idiotype vaccines and personalised for patients with first relapse follicular lymphoma. The trials demonstrated clinical efficacy on managing to change the progress of the illness.More than 2,400 new cases each year in Spain
In this way, the new treatment currently being tested by the University of Navarra Hospital is trying to load the dendritic cells, responsible for directing and co-ordinating the immunity of the organism, with undesired tumour antigens, so that the cells of the immune system are activated and the body’s defences are aimed at the remains of the tumour at a time when tumour cells are scarcer, i.e. after the extirpation of the tumour and the application of radio-chemotherapy.Multidisciplinary work
An essential condition is also that patients have not previously received any kind of an treatment for glioblastoma, except a biopsy or an partial extirpation surgery. The compliance with this premise is necessary as, for the production of the personalised vaccines, the greatest quantity possible of the tumour tissue must be obtained. Moreover, the extirpation of the tumour should be undertaken in the most complete possible manner, given that it has been demonstrated that, the cases in which the immunotherapy has proved effective are those in which wide-ranging extirpations have taken place.Total extirpation with fluorescent microscope
In concrete, the surgical fluorescent microscope has enabled specialists at the Hospital to reach the total extirpation of glioblastomas in more than 80% of the cases operated over the last two years. After the extirpation, the tumour tissue obtained has to be sent - in conditions of maximum sterility - directly to the Pathological Anatomy Laboratory to corroborate or contradict the diagnosis. If the tumour is confirmed to be a glioblastoma, the tumour tissue is then transferred to the Cell Therapy GMP Laboratory at the Hospital for its processing and the subsequent obtaining of personalised vaccines produced with the tissue of each patient taking part in the clinical trials.Production of personalised vaccines
The dendritic cells are obtained by a process known as leukapheresis which involves the separation and extraction of white blood cells from the rest of the patient’s blood, and returning it to the organism.
After the pheresis and by means of immunomagnetic selection, monocytes are obtained - a type of white blood cell the function of which in the body is to pass to the tissues, converting themselves into dendritic cells and capture antigens (molecules capable of triggering an immune response), amongst these tumoural antigens. Once captured, the dendritic cells teach the lymphocytes (the cells responsible for immune responses) to recognise cancer cells and destroy them at any point of the organism. This immunomagnetic procedure involves adding a small metal ball to some antibodies specific to the monocytes. When these antibodies adhere to the monocytes, it only needs the application of a magnetic field to achieve the separation and extraction of the monocytes from the rest of the white blood cells.
Once the monocytes are selected, they are cultured for eight days – at the same Cell Therapy Laboratory, under similar conditions to those of the organism itself. After this period of culture, the monocytes, to which cytokines have been added (regulatory proteins of the immune system cells), change into dendritic cells, fundamental for the l functioning of this immune system.Processing the tumour
Once the proteins from the glioblastoma are obtained, these are incubated with the immune system dendritic cells in order to be processed and the components of the tumour proteins placed in their membrane. In this manner the vaccine is produced, in such as way that, when the patient is injected, the lymphocytes of the blood will detect the tumour particles in the membrane and generate an immune system response against the cells of the glioblastoma.Vaccines combined with standard treatment
The usual treatment for these tumours involves extirpation by surgery, followed by a combination of radio and chemotherapy of five weeks and then between six and twelve cycles of chemotherapy (administered once every four weeks). The cell vaccines are administered by intradermally simultaneously with these treatments, once a month at first, then bimonthly and the final dose every three months.
Oihane Lakar | EurekAlert!
Tracking movement of immune cells identifies key first steps in inflammatory arthritis
23.01.2017 | Massachusetts General Hospital
Team discovers how bacteria exploit a chink in the body's armor
20.01.2017 | University of Illinois at Urbana-Champaign
For the first time ever, a cloud of ultra-cold atoms has been successfully created in space on board of a sounding rocket. The MAIUS mission demonstrates that quantum optical sensors can be operated even in harsh environments like space – a prerequi-site for finding answers to the most challenging questions of fundamental physics and an important innovation driver for everyday applications.
According to Albert Einstein's Equivalence Principle, all bodies are accelerated at the same rate by the Earth's gravity, regardless of their properties. This...
An important step towards a completely new experimental access to quantum physics has been made at University of Konstanz. The team of scientists headed by...
Yersiniae cause severe intestinal infections. Studies using Yersinia pseudotuberculosis as a model organism aim to elucidate the infection mechanisms of these...
Researchers from the University of Hamburg in Germany, in collaboration with colleagues from the University of Aarhus in Denmark, have synthesized a new superconducting material by growing a few layers of an antiferromagnetic transition-metal chalcogenide on a bismuth-based topological insulator, both being non-superconducting materials.
While superconductivity and magnetism are generally believed to be mutually exclusive, surprisingly, in this new material, superconducting correlations...
Laser-driving of semimetals allows creating novel quasiparticle states within condensed matter systems and switching between different states on ultrafast time scales
Studying properties of fundamental particles in condensed matter systems is a promising approach to quantum field theory. Quasiparticles offer the opportunity...
19.01.2017 | Event News
10.01.2017 | Event News
09.01.2017 | Event News
23.01.2017 | Health and Medicine
23.01.2017 | Physics and Astronomy
23.01.2017 | Process Engineering